Information on this website is provided for informational purposes only and is not a substitute for professional medical advice.
While there are currently no medications are available to reduce Lp(a) levels, research is in progress to develop and trial medications that may achieve this.
Monash Health in the media: breakthroughs for previously untreatable cholesterol - Monash Health
The latest on lipoprotein(a), an inherited cause of early heart disease - Harvard Health
One of the main barriers to testing in Australia is the lack of MBS reimbursement. The cost of the Lp(a) test has to be shouldered by the patient and this therefore limits widespread uptake.
Randomised clinical trials can demonstrate the clinical benefit from Lp(a) reduction therapies.
HORIZONS, the first clinical trial, is due to report in 2026, and centres around a new agent called Pelacarsen.
Details of the HORIZONS trial: https://clinicaltrials.gov/study/NCT04023552
Clinical rationale for the trial: https://pubmed.ncbi.nlm.nih.gov/40185318/